Plasma norepinephrine and mortality

Jay N. Cohn

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Plasma norepinephrine levels, which reflect sympathetic nervous system activity, are almost universally elevated in patients with left ventricular dysfunction. This elevation occurs in patients with overt, symptomatic heart failure (HF) and in patients with asymptomatic left ventricular dysfunction. Evidence suggests that the elevation in plasma norepinephrine levels can be at least partly attributed to an increase in sympathetic nervous system activity. It has become evident that elevated plasma norepinephrine levels are directly related to prognosis; patients with levels > 900 pg/ml have a poor prognosis and shortened life expectancy. However, plasma norepinephrine levels bear little relationship to physiologic and clinical variables observed in HF, including ejection fraction and exercise capacity. Data from the V‐HeFT II show that at 2‐year follow‐up, a progressive rise of plasma norepinephrine was observed in both treatment arms, suggesting that disease progresses despite treatment with either an angiotensin‐converting enzyme inhibitor, enalapril, or vasodilator therapy with hydralazine/isosorbide dinitrate. It is possible that interventions aimed at the progressive neurohormonal activation that occurs in HF may improve the course of illness. Further study is needed to test this hypothesis.

Original languageEnglish (US)
Pages (from-to)I-9-I-12
JournalClinical Cardiology
Volume18
Issue number1 S
DOIs
StatePublished - Mar 1995

Keywords

  • V‐HeFT
  • heart failure
  • neurohormonal activation
  • norepinephrine
  • sympathetic nervous system

Fingerprint Dive into the research topics of 'Plasma norepinephrine and mortality'. Together they form a unique fingerprint.

Cite this